Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-pacific hepatitis C virus genotype 1 non-responders/relapsers

Figure 1 Treatment responses. A: End of treatment (ETR) and sustained virological response at week 12 (SVR12) in prior treatment failures (non-responders [partial and null responders] and relapsers or miscellaneous), and in all patients; B: Undetectable HCV RNA at week 4, 8 and 12 in non-responders, relapsers, treatment naïve and miscellaneous and overall patients groups; C: ETR and SVR rates in Asians vs Caucasians in prior relapsers (Asian = 51; Caucasians = 28) and non-responders (Asian = 32; Caucasians = 20). Only significant differences are shown.

Figure 2 Sustained virological response by on-treatment response. A: SVR based on undetectable hepatitis C virus (HCV) RNA at week 4, 8 and 12 compared with detectable HCV RNA at the same time points; B: SVR in Asians compared with Caucasians when HCV RNA was undetectable at treatment week 4, 8 or 12 compared with those with detectable HCV RNA at the same time points. Significant differences are shown. Only significant differences are shown.

Figure 3 Sustained virological response by IL28B genotype. A: Sustained virological response (SVR) rates by IL28B CC vs non-CC genotypes; B: SVR rates in Asians vs Caucasians by IL28B CC vs non-CC genotype; C: SVR by undetectable hepatitis C virus (HCV) RNA at treatment week 4, 8 and 12 comparing IL28B CC vs non-CC genotype; D: SVR in prior non-responders and relapsers comparing IL28B CC vs non-CC genotypes. Significant differences are shown.

Figure 4 Sustained virological response by Cirrhosis. A: Sustained virological response (SVR) in cirrhotic patients (n = 69), based on their on-treatment response at week 4, 8 and 12; B: SVR rates in cirrhotics based on their on-treatment responses, comparing Asians (n = 30) vs Caucasians (n = 39). Significant differences are shown.